Northwest Biotherapeutics (NWBO) Common Equity (2016 - 2025)
Historic Common Equity for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to -$108.6 million.
- Northwest Biotherapeutics' Common Equity fell 3561.17% to -$108.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$108.6 million, marking a year-over-year decrease of 3561.17%. This contributed to the annual value of -$94.5 million for FY2024, which is 4365.62% down from last year.
- Per Northwest Biotherapeutics' latest filing, its Common Equity stood at -$108.6 million for Q3 2025, which was down 3561.17% from -$100.4 million recorded in Q2 2025.
- In the past 5 years, Northwest Biotherapeutics' Common Equity registered a high of -$56.0 million during Q1 2023, and its lowest value of -$1.3 billion during Q3 2023.
- Over the past 5 years, Northwest Biotherapeutics' median Common Equity value was -$100.4 million (recorded in 2025), while the average stood at -$196.8 million.
- Its Common Equity has fluctuated over the past 5 years, first plummeted by 113632.89% in 2023, then surged by 9404.66% in 2024.
- Over the past 5 years, Northwest Biotherapeutics' Common Equity (Quarter) stood at -$124.0 million in 2021, then decreased by 3.32% to -$128.1 million in 2022, then skyrocketed by 48.66% to -$65.8 million in 2023, then crashed by 43.66% to -$94.5 million in 2024, then decreased by 14.99% to -$108.6 million in 2025.
- Its Common Equity was -$108.6 million in Q3 2025, compared to -$100.4 million in Q2 2025 and -$99.5 million in Q1 2025.